How certain proteins affect cancer treatment sensitivity in yeast
Official title: Impact of Solute Carriers on Ruthenium Complex Sensitivity in Yeast
Funded at Furman University · NIH-10360056 · Data updated 2026-11-12
This study is looking at how certain proteins in yeast help the cells respond to a new cancer drug called KP1019, which could help us learn more about why some cancer treatments work better than others.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Furman University NIH-funded |
| Lab location | 1 site (Greenville, United States) |
| Project start | January 3, 2022 |
| Project end | December 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $299,191 |
| NIH project number | 1R15CA260456-01A1 |
| Project ID | NIH-10360056 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with cancers that may be treated with ruthenium-based drugs or those interested in the mechanisms of drug resistance.
✕Less likely to help
Patients with non-cancerous conditions or those not affected by drug resistance mechanisms may not benefit from this research.
What this research studies
This research investigates the role of solute carriers, a group of proteins, in how yeast cells respond to a promising anticancer drug called KP1019. By using yeast as a model organism, the study aims to understand the mechanisms behind the induction of a specific protein, Tpo1, when exposed to KP1019. The researchers will explore how the absence of Tpo1 affects the yeast's resistance to this drug and identify other factors that may influence this sensitivity. This work could provide insights into improving cancer treatment strategies by understanding drug resistance mechanisms.
Why it matters
Potential benefit: If successful, this research could lead to better understanding of drug resistance in cancer treatments, potentially improving therapeutic outcomes for patients.
How similar studies have gone: While the specific approach of studying solute carriers in relation to KP1019 is novel, similar research has shown that understanding drug transport mechanisms can lead to advancements in cancer treatment.
Where this research is happening
-
Furman University
Greenville, United States Active
Researchers
- Principal investigator: Hanson, Pamela — Furman University
- Study coordinator: Hanson, Pamela
Related research
Other NIH-funded projects on the same topics.
-
Understanding how Desmoglein-2 affects cell movement and gene expression.
This study is looking at a protein called Desmoglein-2 to understand how it helps cells move and interact with their surroundings, which could provide helpful information for patients about how cell movement affects different diseases.
-
Exploring how sex differences and gut bacteria affect eating behaviors
This study is looking at how the bacteria in our gut might affect why we eat certain foods for pleasure, especially tasty, high-fat ones, and it wants to see if there are differences between men and women in these eating habits, particularly to help understand obesity in women.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.